MORGANTOWN, W.Va. – The WVU Cancer Institute is enrolling patients in an innovative clinical trial to treat ovarian cancer.
Valerie Galvan Turner, M.D., gynecologic oncologist at the WVU Cancer Institute, will help lead the trial to evaluate the efficacy of varying dosages and combinations of the cancer medications pegylated liposomal doxorubicin (PLD), atezolizumab, and bevacizumab in the treatment of ovarian cancer.
“We are excited to bring this clinical trial to West Virginia and the WVU Cancer Institute,” Dr. Galvan Turner said. “This treatment has the potential to allow for more options for patients for whom other treatments may not be effective.”
The clinical trial is open to epithelial ovarian cancer patients whose cancer recurred less than one year after completing their first treatment or line of chemotherapy and are considered platinum resistant.
All participants will receive treatment, but the types of treatment will be randomly assigned.
“The WVU Cancer Institute is dedicated to expanding the field of knowledge of cancer treatment,” Galvan Turner said. “We hope this study will help advance the field and provide more options for patients with ovarian cancer.”
The WVU Medicine/The Health Plan SecureCare (HMO) is a Medicare Advantage HMO that covers all aspects of healthcare, including preventive care, doctor visits, hospital stays, and surgery.
WVU Medicine will host a community day from 10 a.m. to 2 p.m. on Saturday, Oct. 26, at its new outpatient clinic on Murtha Drive in Waynesburg, Pa.
WVU Medicine J.W. Ruby Memorial Hospital will host an open house to introduce community members to Project SEARCH and recruit for its 2020 class from 6:30 to 8 p.m. on Tuesday, Oct. 15, in the Bruce McClymonds Conference Room. Potential participants and their families will have the opportunity to meet the staff and instructor and learn more about the internship program.